Shannon E. McKernin

TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.

TL;DR: The Expert Panel continues to recommend ER testing of invasive breast cancers by validated immunohistochemistry as the standard for predicting which patients may benefit from endocrine therapy, and no other assays are recommended for this purpose.

TL;DR: This guideline update is to incorporate recently reported practice-changing evidence into ASCO's recommendations on potentially curable pancreatic adenocarcinoma and updated Recommendation 4.1, which states that all patients with resected pancreatic cancer who did not receive preoperative therapy should be offered 6 months of adjuvant chemotherapy in the absence of medical or surgical contraindications.

TL;DR: This PCO addresses identification and management of patients and family members with possible predisposition to pancreatic adenocarcinoma and offers timely clinical direction to ASCO's membership and other health care providers.

TL;DR: The concordance between the frameworks was higher than observed in other studies that sought to compare them and suggest potential approaches to improve convergence between the scales.